Lesson 9 - ADHD Medication Monitoring
1. Introduction
Starting medication for ADHD is only the beginning of pharmacological treatment. Safe and effective prescribing requires ongoing monitoring to establish whether medication is helping, whether the dose remains appropriate, whether adverse effects are developing, and whether treatment continues to provide meaningful benefit in the person's everyday life.
Monitoring ADHD medication is therefore much more than checking blood pressure, pulse, height or weight. These measurements are important, but good monitoring also involves reviewing ADHD symptoms, functional improvement, duration of medication effect, adherence, sleep, appetite, mood, behaviour and possible adverse effects. It also requires clinicians to remain alert to cardiovascular concerns, changes in mental state and the potential for misuse or diversion of stimulant medication.
A common mistake in clinical practice is to focus primarily on whether somebody is "better" on medication. The more useful question is whether the current treatment provides a worthwhile balance between benefit and harm. A medication may improve concentration but cause unacceptable appetite suppression. Another may work extremely well during school or working hours but wear off before the person needs to manage responsibilities at home. Conversely, somebody may experience a mild adverse effect that is acceptable to them because the overall improvement in functioning is substantial.
Monitoring therefore requires clinical judgement. Measurements and rating scales can support decision-making, but they cannot replace a careful clinical review.
The approach also changes over time. During titration, monitoring is relatively frequent because the clinician is actively establishing the most appropriate medication and dose. Once treatment is stable, reviews can usually become less frequent, but monitoring must continue. ADHD medication should not simply remain on repeat prescription indefinitely without periodically reconsidering its effectiveness, tolerability and ongoing clinical need.
This lesson builds on the course teaching about ADHD medication and titration. It focuses on what prescribers should monitor, how frequently monitoring should take place, how to interpret changes in physical and mental health, and how to respond when concerns arise.
Particular attention will be given to stimulant medications, atomoxetine and guanfacine, recognising that each has a different adverse-effect profile and therefore requires somewhat different clinical considerations. We will also consider the distinction between routine findings that can usually be managed within an ADHD clinic and findings that should prompt treatment modification, further investigation or specialist medical assessment.
By the end of the lesson, the aim is for monitoring to feel less like a checklist and more like an active clinical process. The prescriber should be able to answer three fundamental questions at every medication review:
Is the medication providing meaningful benefit?
Is the medication causing any clinically important harm?
Does the current treatment plan remain appropriate for this individual?
Keeping these questions at the centre of medication monitoring helps ensure that ADHD pharmacological treatment remains safe, individualised and clinically useful throughout the course of care.
2. Learning Outcomes
By the end of this lesson, learners should be able to:
Explain the purpose of ongoing monitoring during both ADHD medication titration and maintenance treatment.
Assess treatment effectiveness by considering changes in core ADHD symptoms, functional outcomes, duration of medication effect and the individual's treatment goals.
Monitor relevant physical health parameters, including blood pressure, pulse, height, weight and growth, and recognise when findings require further assessment or intervention.
Identify and assess common and clinically significant adverse effects associated with stimulant medication, atomoxetine and guanfacine.
Recognise important cardiovascular, psychiatric and other clinical warning signs that may require medication adjustment, treatment interruption, further investigation or referral.
Conduct a structured ADHD medication review that integrates treatment benefit, adverse effects, adherence, patient preference, physical health monitoring and ongoing clinical need.
3. The Lecture
Monitoring Is an Active Part of Treatment
When we prescribe medication for ADHD, monitoring should not be thought of as an administrative requirement that happens alongside treatment. Monitoring is part of the treatment itself.
At every review, we are essentially trying to answer three questions:
Is the medication working?
Is it causing harm or unacceptable adverse effects?
Does the balance between benefit and harm still justify the current treatment?
That sounds straightforward, but good medication monitoring requires considerably more clinical judgement than simply recording a blood pressure and pulse.
NICE recommends monitoring both the effectiveness of ADHD medication and adverse effects, with findings documented in the clinical record. Standard symptom and adverse-effect rating scales can be considered throughout treatment, but they should complement rather than replace clinical assessment.
The approach to monitoring will also change over time. During titration, we usually monitor relatively frequently because we are actively trying to establish the most appropriate dose. Once treatment has stabilised, reviews can become less frequent, but monitoring must continue.
Begin With Effectiveness
One of the most important principles in ADHD prescribing is that we are treating impairment, not simply trying to reduce a symptom score.
Imagine a 14-year-old taking modified-release methylphenidate. His parents tell you that he is "much calmer".
That sounds encouraging, but it is not enough information to establish whether treatment is effective.
We need to understand what has actually changed.
Can he concentrate for longer in lessons? Is he completing more work? Is he receiving fewer sanctions? Can he organise himself more effectively? Are relationships at home improving? Can he complete homework? Is he less impulsive around peers?
Similarly, an adult might say that medication has improved concentration, but the clinically important question is what this means functionally. Are they completing tasks at work? Missing fewer deadlines? Managing household responsibilities more effectively? Driving more safely? Following conversations? Remembering appointments?
The aim is meaningful improvement in everyday functioning.
Ask About Core ADHD Symptoms
A medication review should consider both inattentive and hyperactive-impulsive symptoms.
For inattention, ask about difficulties such as concentration, distractibility, task completion, organisation, forgetfulness and losing things.
For hyperactivity and impulsivity, consider restlessness, interrupting, acting without thinking, excessive talking, difficulty waiting and impulsive decision-making.
The relative importance of these symptoms will vary enormously between individuals.
A useful review therefore compares current functioning with the person's baseline rather than simply asking whether ADHD symptoms remain present.
Complete disappearance of ADHD symptoms is not usually a realistic treatment target. We are looking for clinically meaningful improvement with acceptable adverse effects.
Look Beyond Symptoms to Function
A person can improve symptomatically without experiencing sufficient functional benefit.
For children and young people, consider functioning at school, at home, socially and during extracurricular activities.
For adults, consider employment or education, relationships, parenting, household responsibilities, finances, driving and general daily organisation.
This is also where collateral information can sometimes be particularly valuable.
A young person may notice relatively little difference themselves, while school reports a substantial improvement in classroom engagement. Conversely, parents may report considerable improvement at home while school continues to describe significant difficulties.
These differences are not necessarily contradictions. ADHD impairment varies according to environmental demands, structure, time of day and medication coverage.
Establish When the Medication Works
Do not only ask whether medication works. Ask when it works.
For stimulant medication particularly, understanding the timing of benefit is essential.
Ask:
When do they first notice an effect?
How long does the useful effect last?
When does it appear to wear off?
What happens when it wears off?
Are important parts of the day inadequately covered?
A child may be doing very well between 9 am and 3 pm but experiencing significant difficulties during homework and family routines in the evening.
An adult may function extremely well during the working day but find that the medication wears off just as they return home and need to manage parenting, cooking and household responsibilities.
That does not necessarily mean the medication is ineffective. It may indicate that the duration of action does not match the person's functional needs.
Monitor Adverse Effects Systematically
Do not rely solely on the question:
"Any side effects?"
People may answer "no" because they do not realise that something they are experiencing could be medication-related.
Instead, ask specifically about the adverse effects that are relevant to the medication being prescribed.
With stimulant medication, this commonly includes appetite suppression, weight change, sleep disturbance, headaches, abdominal discomfort, increased heart rate, increased blood pressure, irritability and possible changes in mood.
You should also remain alert to less common but potentially important problems such as cardiovascular symptoms, significant psychiatric changes, seizures, tics and concerns regarding misuse or diversion.
For atomoxetine, monitoring should include appetite, weight, sleep, gastrointestinal effects, cardiovascular parameters and mental state. The product information specifically advises monitoring for the appearance or worsening of suicide-related behaviour. Rare hepatic injury is also recognised, although routine liver-function testing is not recommended in the absence of a clinical indication.
With guanfacine, particular attention should be paid to sedation, somnolence, dizziness, bradycardia, hypotension and syncope. Its cardiovascular profile is therefore different from stimulant medication and atomoxetine.
Appetite and Weight
Appetite suppression is one of the adverse effects clinicians encounter most frequently with stimulant medication.
The important issue is not simply:
"Has their appetite reduced?"
Instead ask:
When is appetite reduced?
Are they still eating breakfast?
What happens at lunchtime?
Does appetite return in the evening?
Has their actual weight changed?
Is growth being affected?
A child who eats very little at lunchtime but has a good breakfast, substantial evening meal and appropriate growth trajectory may require a different response from a child who is progressively crossing down weight centiles.
NICE recommends measuring weight every 3 months in children aged 10 years and under. For children and young people over 10 years, weight should be measured at 3 and 6 months after starting treatment and every 6 months thereafter, or more often if concerns arise. Adults should have their weight measured every 6 months. Height should be measured every 6 months in children and young people, with height and weight plotted on an appropriate growth chart.
What Should We Do About Weight Loss?
The first response to appetite suppression does not necessarily need to be stopping an otherwise effective medication.
Think practically.
Could medication be taken with or after food rather than before eating?
Could breakfast be made more substantial before the medication takes full effect?
Could additional food be offered later in the day when the medication effect is reducing?
Would dietary advice be useful?
NICE suggests strategies including taking medication with or after food, additional meals or snacks when stimulant effects have worn off, dietary advice, nutritionally appropriate high-calorie foods, changing medication or considering a planned treatment break where clinically appropriate.
The decision depends on the severity and persistence of the problem and the benefits being obtained from treatment.
Growth in Children and Young People
Growth requires longitudinal monitoring.
One isolated height measurement tells us relatively little. We need to know the trajectory.
This is why plotting height and weight is important.
If a child's growth becomes significantly affected by medication, NICE recommends considering a planned break from treatment over school holidays to allow catch-up growth.
Again, this requires clinical judgement. A planned medication break should have a purpose rather than becoming an automatic response to every minor change in appetite or weight.
Blood Pressure and Pulse
Cardiovascular monitoring is a routine part of ADHD prescribing.
NICE recommends monitoring heart rate and blood pressure before and after each dose change and every 6 months thereafter, comparing measurements with the normal range for age.
Do not interpret the number without context.
If a measurement is unexpectedly elevated, consider whether the person has just rushed into the clinic, is anxious, has consumed caffeine or an energy drink, or whether the measurement technique was appropriate.
Repeat unexpected measurements when appropriate.
At the same time, do not dismiss persistent abnormalities simply because the person feels well.
NICE advises that sustained resting tachycardia above 120 beats per minute, an arrhythmia, or systolic blood pressure above the 95th percentile or a clinically significant increase measured on two occasions should lead to dose reduction and referral to an appropriate paediatric or adult physician.
Ask About Cardiovascular Symptoms
Physical observations do not replace clinical history.
Ask about new palpitations, chest pain, syncope, exertional symptoms and other clinically significant cardiovascular symptoms.
A person may have normal observations during a 30-minute appointment but describe episodes outside the clinic that require investigation.
New cardiovascular symptoms should therefore be assessed on their clinical merits rather than waiting for the next routine monitoring appointment.
Routine ECGs and Blood Tests Are Usually Unnecessary
Another common misconception is that people taking ADHD medication require routine ECGs or regular blood tests.
NICE does not recommend routine ECGs or blood tests, including liver-function tests, for people taking ADHD medication unless there is a clinical indication.
This distinction matters.
Good monitoring does not mean performing every possible investigation. It means performing appropriate monitoring and investigating when the history, examination, observations or clinical circumstances provide a reason to do so.
Sleep
Sleep should be reviewed throughout treatment.
Ask what time the person takes medication, what time they go to bed, how long they take to fall asleep, whether they wake during the night and what their sleep was like before medication started.
This final question is particularly important.
Sleep problems are extremely common in ADHD. If somebody already took two hours to fall asleep before starting medication, it would be misleading to automatically attribute the same problem to their medication.
Equally, if sleep deteriorates clearly after a dose increase, medication timing, dose and duration of action should be considered.
NICE recommends monitoring changes in sleep pattern, for example using a sleep diary, and adjusting medication accordingly.
Mood and Mental State
Medication reviews should always include mental state.
Ask about irritability, anxiety, emotional changes, low mood, agitation and any unusual changes in behaviour.
Be particularly careful about temporal relationships.
Did the problem exist before medication?
Did it appear after starting treatment?
Did it worsen after a dose increase?
Does it occur when medication is active or as it wears off?
This helps distinguish a medication adverse effect from the person's underlying ADHD or a coexisting mental health condition.
New psychotic or manic symptoms require particular attention. Significant changes in mental state should prompt a careful assessment of the possible relationship with medication and appropriate action rather than simply continuing treatment unchanged.
Tics
Tics provide a good example of why monitoring requires judgement rather than automatic rules.
Tics naturally fluctuate over time. If a tic appears while someone is taking stimulant medication, this does not automatically prove that the medication caused it.
NICE recommends considering whether the tic is actually related to stimulant treatment and whether tic-related impairment outweighs the benefits of ADHD treatment. If stimulant-related tics are clinically significant, options can include dose reduction, switching medication or considering an alternative treatment.
The key is to assess chronology, severity and impairment.
Seizures
A new seizure or clinically significant worsening of an existing seizure disorder requires careful assessment.
NICE advises reviewing ADHD medication if seizures develop or worsen and stopping medication that might be contributing. Medication may potentially be cautiously reintroduced if seizures are subsequently controlled and the clinical circumstances support doing so.
This is a situation where communication with the person's wider medical team may be particularly important.
Monitoring Atomoxetine
Atomoxetine requires some additional considerations.
Unlike stimulant medication, improvement can develop progressively rather than being clearly apparent within hours of an individual dose. Reviews therefore need to consider the trajectory of response over time.
Blood pressure and pulse should be monitored after dose adjustments and at least every 6 months once treatment is established.
Ask about gastrointestinal symptoms, appetite, sleep, fatigue, mood and cardiovascular symptoms.
Be alert to new or worsening suicidal thoughts or behaviour, particularly in children and adolescents.
Very rare liver injury has also been reported. Routine liver-function testing is not required without clinical indication, but symptoms or signs suggesting hepatic dysfunction should prompt appropriate assessment. Atomoxetine should be stopped in patients who develop jaundice or laboratory evidence of liver injury and should not be restarted in that situation.
Monitoring Guanfacine
Guanfacine requires a somewhat different mindset because it can lower rather than increase heart rate and blood pressure.
Monitor for hypotension, bradycardia, dizziness, sedation and syncope.
During titration and stabilisation, the current UK product information recommends weekly monitoring of heart rate and blood pressure, with at least three-monthly monitoring during the first year and six-monthly monitoring thereafter, with more frequent assessment following dose adjustment.
NICE specifically advises that sustained orthostatic hypotension or fainting while taking guanfacine should lead to dose reduction or switching to another ADHD medication.
Guanfacine should also not simply be stopped abruptly. Its product information advises gradual dose reduction because blood pressure and pulse can increase following discontinuation.
Misuse and Diversion
Monitoring stimulant medication also includes considering how the medication is actually being used.
Ask whether medication is being taken as prescribed.
Be alert to unexpectedly frequent requests for replacement prescriptions, claims of repeatedly lost medication, requests for unusual dose changes or other changes in behaviour that may indicate misuse.
The risk of diversion can change as circumstances change. Adolescence, university, shared accommodation and environments where stimulant medication may be sought by others can alter risk.
NICE recommends monitoring changes in the potential for stimulant misuse and diversion as circumstances and age change.
This should be approached proportionately and without assuming that every prescribing irregularity represents misuse.
Adherence Matters
When treatment appears ineffective, establish whether the medication is actually being taken.
Ask how many doses are missed.
Ask what happens at weekends.
Ask whether the person intentionally takes medication only on certain days.
Ask whether adverse effects are leading them to avoid it.
Ask whether they can remember to take it.
There is little value increasing the dose of a medication that is only being taken intermittently because the person cannot remember their morning dose.
Non-adherence is not simply a patient behaviour problem. It may tell us something important about tolerability, medication timing, treatment expectations or the practical complexity of the regimen.
Medication Reviews Should Be Individualised
A good medication review should bring all of these strands together.
Consider:
What has improved?
What remains difficult?
When does the medication work?
How long does it last?
What adverse effects are present?
What are the current physical observations?
Has weight or growth changed?
How is sleep?
Has mental state changed?
Is medication being taken as intended?
Are there concerns about misuse or diversion?
Does the person still want treatment?
And, finally:
Does the current balance of benefit and harm justify continuing the medication at this dose?
Clinical Example: The Medication Works, but Appetite Is Poor
Consider a 12-year-old taking modified-release methylphenidate.
School describes a dramatic improvement in concentration and task completion. Behaviour at home has also improved. However, he rarely eats lunch.
The first question is not simply whether methylphenidate should be stopped.
Look at his growth trajectory. Ask about breakfast and evening intake. Establish whether he is losing weight. Determine whether appetite returns when medication wears off.
If weight and growth remain appropriate, practical dietary strategies and closer monitoring may be sufficient.
If weight is progressively falling despite intervention, the balance changes and medication adjustment may become necessary.
The same adverse effect therefore produces different clinical decisions depending on its consequences.
Clinical Example: The Blood Pressure Is Elevated
Now consider a 35-year-old taking lisdexamfetamine.
Their blood pressure was normal before treatment but is elevated at review.
Do not immediately increase the medication simply because ADHD symptoms remain partially controlled.
Repeat the measurement appropriately. Consider the magnitude and persistence of the change, other cardiovascular risk factors and whether the increase appears medication-related.
Persistent clinically significant elevation requires action.
This illustrates an important prescribing principle: increasing benefit is not always worth increasing physiological risk.
Clinical Example: "It Stops Working at Four"
A 16-year-old tells you:
"The medication works really well, but by four o'clock it's completely gone."
That is very different from:
"The medication doesn't work."
The first description suggests a duration-of-action problem.
Ask what happens after 4 pm. Does homework become impossible? Does impulsivity return? Is evening family life significantly affected?
Treatment decisions should reflect the person's whole day rather than only the hours spent in school.
The Annual Medication Review
Even when somebody has been stable for a long time, medication should not become an automatic repeat prescription.
NICE recommends reviewing ADHD medication at least annually with the person, involving parents or carers where appropriate. The review should consider the person's preferences, benefits of treatment, adverse effects, clinical need, impact on education or employment, effects of missed doses or periods without treatment, and whether medication optimisation or discontinuation should be considered.
The question is not:
"Are they still taking it?"
The question is:
"Does this remain the right treatment?"
Monitoring Is About Trends, Not Isolated Numbers
One of the most useful habits to develop as an ADHD prescriber is to think longitudinally.
A blood pressure reading means more when compared with previous readings.
Weight means more when viewed as a trajectory.
A symptom score means more when compared with baseline.
An adverse effect means more when considered in relation to dose changes.
Functional improvement means more when considered across several months.
Good ADHD medication monitoring therefore involves repeatedly bringing together symptoms, functioning, adverse effects, physical health and the person's own experience of treatment.
The aim is not to eliminate every possible adverse effect.
Nor is it simply to achieve the maximum possible reduction in ADHD symptoms.
The aim is to find and maintain a treatment regimen in which meaningful functional benefit is achieved with an acceptable burden of adverse effects and an appropriate level of clinical risk.
That balance is at the heart of safe ADHD prescribing.
4. Clinical Perspective
Clinical Pearls
The most important principle in ADHD medication monitoring is to monitor the person, not simply the prescription.
It is entirely possible to have normal blood pressure, pulse and weight while prescribing medication that is providing very little meaningful benefit. Equally, a medication may be highly effective but produce adverse effects that make the current dose unsustainable. Physical observations are essential, but they are only one part of the review.
Always establish what has changed in everyday life. Rather than asking only whether concentration is better, ask what the person can now do that they could not reliably do before treatment. For a child, this might mean completing lessons, remaining in the classroom or managing homework. For an adult, it might mean meeting deadlines, completing administrative tasks or managing responsibilities at home.
Another useful principle is to establish the timing of both benefits and adverse effects. "The medication isn't working" can mean several different things. It may never have worked, it may work insufficiently, it may work well but for too short a period, or the person may be experiencing difficulties when it wears off. These scenarios require different responses.
Similarly, "poor appetite" is much more useful clinically when translated into a pattern. Does the person eat breakfast? Do they miss lunch? Does appetite return in the evening? Are they actually losing weight? Is a child continuing to follow their expected growth trajectory?
Specific questions produce better prescribing decisions than general questions.
Compare With Baseline
Before attributing a symptom to medication, establish whether it was present before treatment.
This is particularly important for sleep difficulties, anxiety, irritability, headaches, appetite difficulties, emotional dysregulation and tics.
ADHD frequently coexists with other difficulties, and some symptoms naturally fluctuate. Temporal relationships are therefore extremely useful.
Ask:
Did this begin after medication was started?
Did it change after the dose increased?
Does it occur while the medication is active?
Does it appear as the medication wears off?
What happens on days when medication is not taken?
This often provides considerably more useful information than simply asking whether something is a "side effect".
Look at Trends
Do not overreact to a single mildly unusual measurement, but do not ignore a developing pattern.
Weight, height, pulse and blood pressure become more clinically useful when considered longitudinally.
A single slightly elevated pulse in an anxious teenager who has just hurried into clinic is very different from progressively increasing resting heart rates recorded across several appointments.
Similarly, a small weight fluctuation may be insignificant, whereas progressive weight loss over several months deserves attention.
Whenever possible, look back at previous observations before making a decision.
Repeat Unexpected Observations
If a physical observation does not fit the clinical picture, repeat it.
Blood pressure is particularly vulnerable to measurement error and situational effects. Ensure the person has had an opportunity to sit quietly, use an appropriately sized cuff and repeat an unexpected reading where appropriate.
However, repeating a measurement should not become a way of repeatedly dismissing an abnormal result. Persistent abnormalities need to be acted upon.
Ask About Cardiovascular Symptoms
Normal observations do not exclude clinically important symptoms occurring outside the appointment.
Ask about chest pain, significant palpitations, fainting and relevant exertional symptoms.
A useful rule for newly qualified prescribers is that new cardiovascular symptoms after starting medication or increasing a dose deserve proper clinical assessment rather than reassurance based solely on one normal set of observations.
Where symptoms suggest a potentially significant cardiovascular problem, prioritise safety, reconsider ongoing medication exposure and arrange appropriate medical assessment.
Appetite Suppression Does Not Automatically Mean Stopping Treatment
Reduced appetite is common with stimulant medication, but its clinical significance varies considerably.
A mild reduction in lunchtime appetite with stable weight and appropriate growth is very different from persistent weight loss or faltering growth.
Before abandoning an otherwise effective treatment, consider practical interventions. A substantial breakfast before the medication takes full effect, taking medication with or after food where appropriate, additional evening intake when appetite returns, dietary advice and review of dose or preparation may all be relevant.
The important question is not simply whether appetite has reduced. It is whether the reduction is producing clinically important nutritional or growth consequences.
Do Not Chase Complete Symptom Elimination
One of the easiest mistakes when learning ADHD prescribing is to continue increasing medication because some ADHD symptoms remain.
Medication does not need to remove every ADHD characteristic to be worthwhile.
There will eventually be a point where further dose increases provide relatively little additional benefit but produce increasing adverse effects.
The goal is therefore not the highest tolerated dose. It is the dose that provides the best overall balance of clinically meaningful benefit and tolerability.
Do Not Confuse Duration With Dose
When someone says that their medication "doesn't work in the evening", the immediate response should not necessarily be to increase the morning dose.
First establish whether the medication works adequately earlier in the day.
If it works very well but wears off too early, the problem may be duration rather than insufficient intensity of effect.
This distinction is particularly important with stimulant prescribing. Increasing a dose purely to extend duration can sometimes produce excessive effects earlier in the day without adequately solving the later problem.
Ask About Sleep Properly
"How is your sleep?" often produces very little useful information.
Ask what time the person takes their medication, what time they go to bed, how long they take to fall asleep, whether they wake during the night and what time they wake.
Most importantly, establish what sleep was like before medication.
Do not automatically prescribe another medication to manage insomnia without first considering whether the ADHD medication regimen itself could be contributing.
Remember That Different Medications Require Different Monitoring
Avoid developing a generic "ADHD medication checklist" that is applied identically to every medication.
Stimulants and atomoxetine can increase heart rate and blood pressure.
Guanfacine can reduce blood pressure and heart rate and can cause dizziness, sedation and syncope.
Atomoxetine requires awareness of mental-state changes and the rare possibility of clinically significant hepatic injury.
The monitoring conversation should therefore reflect the pharmacology and adverse-effect profile of the medication being prescribed.
Be Particularly Careful During Dose Changes
Titration is when active monitoring matters most.
A person who has tolerated one dose well has not necessarily demonstrated that they will tolerate the next dose equally well.
After dose changes, specifically ask whether anything changed after the increase.
Did appetite deteriorate?
Did sleep change?
Did anxiety or irritability increase?
Did blood pressure or pulse change?
Did the additional dose actually provide further functional benefit?
If the answer to the final question is no, there may be little justification for accepting additional adverse effects.
Do Not Ignore Mental-State Changes
Medication monitoring is not purely physical-health monitoring.
New or substantial changes in mood, anxiety, agitation, behaviour or thinking should be explored carefully.
The temporal relationship with medication is again important. Establish whether symptoms followed treatment initiation or dose escalation and whether they vary according to medication exposure.
Marked psychiatric deterioration, including possible manic or psychotic symptoms, should not simply be documented and reviewed routinely at the next appointment. It requires prompt clinical assessment and reconsideration of the treatment plan.
Be Curious About Adherence
When medication appears ineffective, do not automatically increase the dose.
First establish how consistently it is being taken.
People miss medication for many reasons. They may forget it, dislike an adverse effect, wake too late to take it, intentionally avoid it at weekends, struggle with swallowing medication or simply not believe that it helps.
Approach this with curiosity rather than criticism.
Understanding why medication is not being taken is usually much more clinically useful than simply documenting "poor compliance".
Monitor Misuse and Diversion Without Becoming Suspicious of Everyone
Stimulants are controlled drugs and misuse and diversion are legitimate prescribing considerations.
However, monitoring should remain proportionate.
An isolated lost prescription does not establish misuse. A developing pattern of repeated losses, unusually early requests, unexplained dose escalation or other concerning behaviour deserves further exploration.
Circumstances also change. A young person moving to university or shared accommodation may suddenly be in an environment where other people seek access to their medication.
Discuss safe storage and never sharing medication as part of routine prescribing rather than waiting until a problem occurs.
Listen to the Patient's Priorities
Prescribers sometimes underestimate how differently people value benefits and adverse effects.
One person may accept mild appetite suppression because medication has transformed their ability to work. Another may find the same adverse effect unacceptable.
A teenager may value being able to concentrate at school but dislike feeling less spontaneous socially.
An adult may prioritise medication coverage into the evening because that is when parenting demands are greatest.
Shared decision-making matters because the "best" pharmacological outcome cannot be determined from symptom scores alone.
Involve Other People Where Appropriate
Collateral information can be extremely valuable, particularly for children and young people.
Parents may describe changes at home while school provides information about classroom functioning.
However, do not simply count reports and decide which side is correct.
Different environments place different demands on executive functioning. Medication may also provide different levels of coverage at different times of day.
Apparently conflicting accounts may therefore contain useful information about when and where treatment is working.
Know When Not to Increase the Dose
Sometimes the correct prescribing decision is to leave the dose unchanged.
Do not increase medication simply because the person has not achieved complete symptom remission.
Pause before increasing when:
The existing dose is already providing substantial functional benefit.
Adverse effects are increasing.
Physical observations are becoming concerning.
There is uncertainty about adherence.
The medication is effective but its duration is inadequate.
The remaining difficulty may be better explained by another condition or environmental factor.
The functional benefit of the proposed increase is unclear.
Prescribing restraint is an important clinical skill.
Avoid Treating Every Problem With Another Prescription
If someone develops insomnia, appetite difficulties, headaches or emotional changes, first consider whether the existing medication regimen can be optimised.
Adding another medication can sometimes be appropriate, but repeatedly prescribing medicines to counteract adverse effects from other medicines can create unnecessary complexity.
Always ask whether adjusting dose, timing, formulation or the original medication would provide a simpler solution.
Document the Clinical Reasoning
Good documentation should allow another clinician to understand why you continued, increased, reduced, switched or stopped medication.
Recording "BP normal, continue medication" provides very little information.
A useful medication review records the important treatment benefits, relevant adverse effects, physical monitoring, adherence, patient preference and the reasoning behind the plan.
This becomes particularly important when care is shared between specialist and primary care services.
Advice for Newly Qualified Doctors
When uncertain, slow the prescribing process down.
There is rarely a need to increase medication simply because a titration schedule says that a higher dose is available.
Ask yourself:
What benefit did the previous increase provide?
What new adverse effects appeared?
What objective monitoring information do I have?
What problem am I trying to solve with the next change?
If you cannot clearly identify the expected benefit of increasing the dose, reconsider whether an increase is necessary.
Equally, do not allow familiarity with ADHD medication to make monitoring mechanical. These medications are prescribed very commonly and are generally manageable with appropriate clinical supervision, but each prescription still requires individualised clinical judgement.
Situations Requiring Greater Clinical Judgement
Particular care is required when treatment benefit is substantial but adverse effects are emerging.
Examples include a child whose ADHD has improved dramatically but whose growth trajectory is becoming concerning, an adult experiencing excellent occupational improvement alongside persistent hypertension, or a young person obtaining major academic benefit but developing significant mood changes.
These situations rarely have meaningful answers based on symptom scores alone.
Consider the severity of ADHD impairment, magnitude of benefit, severity and reversibility of adverse effects, alternative treatments, physical and psychiatric risk, patient preference and the consequences of changing treatment.
Discuss more complex situations with an experienced ADHD prescriber or appropriate specialist rather than feeling that every decision needs to be made independently.
The Question to Finish Every Review With
Before completing an ADHD medication review, mentally ask:
"Knowing what I know today, am I satisfied that continuing this medication at this dose remains clinically justified?"
If the answer is yes, document why.
If the answer is uncertain, identify what additional information or monitoring is required.
If the answer is no, change the treatment plan.
That simple question helps prevent medication monitoring from becoming a routine administrative exercise and keeps the focus where it belongs: maintaining treatment that remains effective, safe, proportionate and appropriate for the individual.
5. Summary
ADHD medication monitoring is an ongoing clinical process that continues from titration through long-term maintenance treatment. Its purpose is to ensure that medication continues to provide meaningful benefit while remaining safe and tolerable.
Effective monitoring should consider more than changes in core ADHD symptoms. Prescribers should assess whether treatment is producing meaningful improvements in everyday functioning, including education, employment, relationships, organisation and daily responsibilities.
The timing and duration of medication effects are also important. When treatment appears inadequate, clinicians should distinguish between insufficient symptom control, inadequate duration of action, inconsistent adherence and difficulties that may not be explained by ADHD.
Adverse effects should be explored systematically rather than relying solely on general questions. Appetite, weight, growth, sleep, cardiovascular effects and mental state should be considered alongside medication-specific concerns.
Physical monitoring remains an essential part of safe prescribing. Blood pressure and pulse should be monitored during dose changes and periodically during maintenance treatment. Children and young people also require appropriate monitoring of height and weight, while weight should continue to be monitored in adults.
Unexpected physical observations should be interpreted in context and repeated where appropriate, but persistent or clinically significant abnormalities should not be ignored. New cardiovascular symptoms, significant mental-state changes, syncope, seizures or other concerning symptoms require appropriate clinical assessment.
Different ADHD medications require different monitoring considerations. Stimulants, atomoxetine and guanfacine have distinct adverse-effect profiles, and monitoring should reflect the medication being prescribed rather than relying on a single generic checklist.
Routine ECGs and blood tests are not required for everyone taking ADHD medication unless there is a clinical indication. Good monitoring means undertaking appropriate investigations when indicated rather than routinely requesting unnecessary tests.
Adherence, safe storage, misuse and diversion should also be considered during ongoing treatment, particularly when circumstances change.
Most importantly, prescribers should avoid automatically increasing medication simply because some ADHD symptoms remain. The aim is not complete symptom elimination or reaching the highest possible dose. The aim is to identify and maintain the treatment regimen that provides the best overall balance between meaningful functional benefit, tolerability, patient preference and clinical safety.
At every medication review, the prescriber should ultimately be able to answer three questions:
Is the medication providing meaningful benefit?
Is it causing clinically important harm or unacceptable adverse effects?
Does continuing this medication at this dose remain appropriate for this individual?
Keeping these questions at the centre of medication monitoring helps ensure that ADHD prescribing remains safe, individualised and clinically purposeful.
5. Summary
ADHD medication monitoring is an ongoing clinical process that continues from titration through long-term maintenance treatment. Its purpose is to ensure that medication continues to provide meaningful benefit while remaining safe and tolerable.
Effective monitoring should consider more than changes in core ADHD symptoms. Prescribers should assess whether treatment is producing meaningful improvements in everyday functioning, including education, employment, relationships, organisation and daily responsibilities.
The timing and duration of medication effects are also important. When treatment appears inadequate, clinicians should distinguish between insufficient symptom control, inadequate duration of action, inconsistent adherence and difficulties that may not be explained by ADHD.
Adverse effects should be explored systematically rather than relying solely on general questions. Appetite, weight, growth, sleep, cardiovascular effects and mental state should be considered alongside medication-specific concerns.
Physical monitoring remains an essential part of safe prescribing. Blood pressure and pulse should be monitored during dose changes and periodically during maintenance treatment. Children and young people also require appropriate monitoring of height and weight, while weight should continue to be monitored in adults.
Unexpected physical observations should be interpreted in context and repeated where appropriate, but persistent or clinically significant abnormalities should not be ignored. New cardiovascular symptoms, significant mental-state changes, syncope, seizures or other concerning symptoms require appropriate clinical assessment.
Different ADHD medications require different monitoring considerations. Stimulants, atomoxetine and guanfacine have distinct adverse-effect profiles, and monitoring should reflect the medication being prescribed rather than relying on a single generic checklist.
Routine ECGs and blood tests are not required for everyone taking ADHD medication unless there is a clinical indication. Good monitoring means undertaking appropriate investigations when indicated rather than routinely requesting unnecessary tests.
Adherence, safe storage, misuse and diversion should also be considered during ongoing treatment, particularly when circumstances change.
Most importantly, prescribers should avoid automatically increasing medication simply because some ADHD symptoms remain. The aim is not complete symptom elimination or reaching the highest possible dose. The aim is to identify and maintain the treatment regimen that provides the best overall balance between meaningful functional benefit, tolerability, patient preference and clinical safety.
At every medication review, the prescriber should ultimately be able to answer three questions:
Is the medication providing meaningful benefit?
Is it causing clinically important harm or unacceptable adverse effects?
Does continuing this medication at this dose remain appropriate for this individual?
Keeping these questions at the centre of medication monitoring helps ensure that ADHD prescribing remains safe, individualised and clinically purposeful.
7. Knowledge Check
Question 1
What is the primary purpose of ongoing ADHD medication monitoring?
A. To ensure that all ADHD symptoms disappear
B. To ensure that the person reaches the maximum licensed dose
C. To establish whether medication continues to provide meaningful benefit with acceptable adverse effects and risk
D. To determine whether medication can be transferred to repeat prescribing as quickly as possible
Correct answer: C
Explanation:
A is incorrect. Complete elimination of ADHD symptoms is not necessarily achievable or required. Treatment should aim for meaningful improvement in symptoms and functioning.
B is incorrect. The aim of titration is not to reach the maximum licensed dose. The appropriate dose is the one that provides the best balance between benefit and adverse effects for the individual.
C is correct. Medication monitoring should continually assess effectiveness, functional benefit, adverse effects, physical and mental health, and whether the overall benefit-risk balance remains favourable.
D is incorrect. Although stable prescribing arrangements are important, monitoring exists primarily to support safe and effective treatment rather than to facilitate repeat prescribing.
Question 2
A 13-year-old taking modified-release methylphenidate has substantially improved concentration and classroom behaviour. His appetite at lunchtime is reduced, but his weight remains stable and he continues to follow his expected growth trajectory. What is the most appropriate initial approach?
A. Immediately stop methylphenidate
B. Continue to monitor growth and weight and consider practical strategies to optimise nutritional intake
C. Ignore the appetite reduction because methylphenidate commonly causes it
D. Immediately change to atomoxetine
Correct answer: B
Explanation:
A is incorrect. Appetite suppression does not automatically require medication to be stopped, particularly when treatment is providing substantial benefit and growth remains satisfactory.
B is correct. The clinical significance of appetite suppression depends on its consequences. Practical measures may include ensuring a good breakfast, taking medication with or after food where appropriate, and increasing nutritional intake when stimulant effects have reduced. Weight and growth should continue to be monitored.
C is incorrect. Common adverse effects still require monitoring. Appetite suppression can become clinically significant if it results in weight loss, nutritional difficulties or impaired growth.
D is incorrect. Switching medication may eventually be appropriate if appetite or growth problems become clinically significant, but it would not usually be the automatic first response in this scenario.
Question 3
According to NICE guidance, how should heart rate and blood pressure generally be monitored in a person taking ADHD medication?
A. Only before medication is started
B. Before and after each dose change and every 6 months during ongoing treatment
C. Every week indefinitely
D. Only if the person develops cardiovascular symptoms
Correct answer: B
Explanation:
A is incorrect. Baseline assessment is important, but cardiovascular monitoring continues after medication has been started.
B is correct. NICE recommends monitoring heart rate and blood pressure before and after each dose change and every 6 months thereafter, with measurements interpreted against the appropriate normal range for age.
C is incorrect. Weekly cardiovascular monitoring indefinitely is not routinely required for all ADHD medications. Monitoring frequency may be greater during titration or in particular clinical circumstances.
D is incorrect. Cardiovascular symptoms should certainly prompt assessment, but routine monitoring is required even when the person is asymptomatic.
Question 4
An adult taking lisdexamfetamine says, "It works really well until about 4 pm, and then everything falls apart." What is the most important issue to clarify before increasing the dose?
A. Whether the medication is effective earlier in the day and whether the main problem is duration of action
B. Whether the patient would prefer the maximum licensed dose
C. Whether all ADHD symptoms have disappeared during the morning
D. Whether an antidepressant should be added
Correct answer: A
Explanation:
A is correct. This history may indicate that the medication is effective but does not provide sufficient duration of coverage. Dose and duration are related but are not the same clinical problem.
B is incorrect. Medication should not be titrated towards the maximum dose simply because that dose is available.
C is incorrect. Complete symptom elimination is not required. The focus should be on clinically meaningful improvement and functioning.
D is incorrect. There is nothing in the scenario to suggest that an antidepressant is required. Adding medication without first understanding the existing regimen would introduce unnecessary complexity.
Question 5
A patient taking ADHD medication has an unexpectedly elevated blood pressure at a routine appointment. What is generally the most appropriate immediate approach?
A. Ignore it if the patient feels well
B. Automatically stop all ADHD medication permanently
C. Check the measurement circumstances and repeat the observation appropriately before interpreting it in the wider clinical context
D. Increase the ADHD medication because anxiety is probably responsible
Correct answer: C
Explanation:
A is incorrect. Clinically significant cardiovascular abnormalities should not be ignored simply because the person is asymptomatic.
B is incorrect. A single unexpected measurement does not necessarily establish a persistent medication-related cardiovascular problem requiring permanent discontinuation.
C is correct. Unexpected observations should be verified appropriately. Consider factors such as recent physical activity, anxiety, caffeine, cuff size and measurement technique. Persistent or clinically significant abnormalities should then be managed according to the clinical findings and relevant guidance.
D is incorrect. It would be unsafe to assume that anxiety explains an abnormal cardiovascular observation and increase the dose without further assessment.
Question 6
Which statement about routine investigations during ADHD medication treatment is most accurate?
A. Everyone taking stimulant medication requires an annual ECG
B. Liver-function tests should be performed every 6 months for everyone taking ADHD medication
C. Routine ECGs and blood tests are not generally required unless there is a clinical indication
D. An ECG should replace routine pulse and blood pressure monitoring
Correct answer: C
Explanation:
A is incorrect. NICE does not recommend routine ECG monitoring for everyone taking stimulant medication in the absence of a clinical indication.
B is incorrect. Routine liver-function testing is not required for everyone taking ADHD medication.
C is correct. Investigations such as ECGs and blood tests should be undertaken when clinically indicated rather than automatically performed in every patient.
D is incorrect. An ECG does not replace routine clinical cardiovascular monitoring. Heart rate and blood pressure remain important components of medication monitoring.
Question 7
Which adverse-effect profile should particularly be considered when monitoring guanfacine?
A. Hypertension and tachycardia only
B. Hypotension, bradycardia, dizziness, sedation and syncope
C. Severe appetite stimulation in every patient
D. Hepatic injury as the principal routine monitoring concern
Correct answer: B
Explanation:
A is incorrect. Guanfacine differs from stimulants because it can lower blood pressure and heart rate.
B is correct. Guanfacine can cause hypotension, bradycardia, dizziness, sedation or somnolence and syncope. These effects are particularly important during titration and following dose adjustments.
C is incorrect. Appetite changes may occur with medications, but severe appetite stimulation is not the defining monitoring concern with guanfacine.
D is incorrect. Hepatic injury is not the principal routine monitoring concern associated with guanfacine. Cardiovascular effects and sedation are particularly important.
Question 8
A patient reports worsening insomnia after their stimulant dose was increased. Which is the best next step?
A. Immediately prescribe a hypnotic medication
B. Establish the timing of medication, onset of insomnia, baseline sleep pattern and relationship between the dose increase and sleep deterioration
C. Reassure the patient that stimulants cannot affect sleep
D. Stop asking about sleep because it is not part of ADHD medication monitoring
Correct answer: B
Explanation:
A is incorrect. Adding another medication should not automatically be the first response. The existing ADHD medication regimen should first be reviewed.
B is correct. Good monitoring establishes chronology. The clinician should determine whether insomnia was present before treatment, whether it changed after the dose increase, when medication is taken and whether medication timing or duration could be contributing.
C is incorrect. Stimulant medication can affect sleep in some individuals, although ADHD itself is also commonly associated with sleep difficulties.
D is incorrect. Sleep is an important component of ongoing ADHD medication monitoring.
Question 9
A university student who has been stable on stimulant medication begins requesting replacement prescriptions because medication has repeatedly been "lost". What is the most appropriate clinical response?
A. Assume immediately that the patient is selling the medication
B. Continue replacing prescriptions indefinitely without discussion
C. Explore the circumstances, reassess the risk of misuse or diversion, discuss safe storage and make a proportionate clinical decision
D. Permanently stop treatment after the first lost prescription
Correct answer: C
Explanation:
A is incorrect. Repeated losses can raise concern about misuse or diversion, but they do not prove that medication is being sold. The concern should be explored objectively.
B is incorrect. Repeated unexplained losses of controlled medication should not simply be ignored.
C is correct. Risk of misuse and diversion can change with circumstances. Moving to university or shared accommodation may alter access to medication by other people. The clinician should explore what is happening, review safe storage and reassess prescribing risk without making unsupported assumptions.
D is incorrect. An isolated lost prescription does not automatically justify permanent discontinuation. Decisions should be proportionate and based on the wider clinical circumstances.
Question 10
A patient has experienced substantial improvement on ADHD medication. Some inattentive symptoms remain, but functioning at work and home has improved considerably. Increasing the dose previously produced more appetite suppression and little additional benefit. What is the most appropriate prescribing principle?
A. Continue increasing until all ADHD symptoms disappear
B. Increase until the maximum licensed dose is reached
C. Maintain the dose if it provides the best overall balance between meaningful benefit and adverse effects
D. Stop medication because residual ADHD symptoms indicate treatment failure
Correct answer: C
Explanation:
A is incorrect. Complete symptom elimination is not the goal of pharmacological treatment and attempts to achieve it may expose the patient to unnecessary adverse effects.
B is incorrect. The maximum licensed dose is a limit rather than a treatment target. There is no clinical reason to reach it if a lower dose provides the optimal response.
C is correct. ADHD medication should be optimised according to the balance between symptom improvement, functional benefit, adverse effects, physical and mental health, and the person's preferences. In this scenario, further increases have produced additional harm without meaningful additional benefit.
D is incorrect. Residual symptoms do not mean that treatment has failed. Substantial functional improvement with acceptable tolerability represents a meaningful treatment response.
Key Message
The purpose of medication monitoring is not simply to complete a physical-health checklist. At each review, the clinician should integrate symptoms, functional improvement, duration of effect, adverse effects, physical observations, mental state, adherence, patient preference and ongoing clinical need.
The central prescribing question remains:
Does this medication, at this dose, continue to provide sufficient meaningful benefit to justify its adverse effects and risks?
That question should guide clinical decision-making throughout titration and long-term ADHD treatment.
